Lercanidipine Hydrochloride Glenmark (Lercanidipine Hydrochloride)

• Lercanidipine Hydrochloride is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure. It helps achieve target blood pressure levels and reduces cardiovascular risk.
• Hypertension: lowers systolic and diastolic blood pressure to recommended targets.
• Isolated systolic hypertension: reduces elevated systolic pressure in older adults.
• Diastolic hypertension: decreases high diastolic pressure in younger patients.

• Lercanidipine Hydrochloride selectively inhibits calcium influx through L‑type calcium channels located on vascular smooth muscle cells. By reducing intracellular calcium, it promotes relaxation of arterial smooth muscle, leading to vasodilation and a consequent decrease in peripheral vascular resistance, which lowers systemic blood pressure.

Lercanidipine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth and redness, usually resolves with continued therapy.
• Peripheral edema: swelling of ankles or lower legs, typically mild.
• Dizziness: may occur when standing quickly.
• Nausea: occasional stomach upset.
• Tachycardia: slight increase in heart rate.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, tongue, or throat, potentially airway‑compromising.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzymes indicating liver stress.
• Allergic reactions: rash, itching, or anaphylaxis.
• Cardiac arrhythmia: irregular heart rhythms in susceptible individuals.

Before initiating therapy with Lercanidipine Hydrochloride, certain precautions should be observed to ensure safe use.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use with caution in patients with liver disease.
• Elderly patients: start at lower doses and monitor for dizziness.
• Concomitant antihypertensives: adjust therapy to prevent additive blood pressure lowering.
• Abrupt discontinuation: taper gradually to avoid rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risking severe hypotension.
• Grapefruit juice: can elevate drug concentration, leading to exaggerated effects.
• Other potent antihypertensives: combined use may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• NSAIDs: can blunt antihypertensive response.
• Diuretics: monitor electrolytes and volume status.
• Beta‑blockers: observe heart rate and blood pressure for additive effects.
• Lipid‑lowering agents (e.g., statins): watch for increased statin levels.